SCHEMBL2477540

SCHEMBL2477540

Cc1c(F)cc(NC(=O)Nc2cccc(-c3nn4ccsc4c3-c3ccncn3)c2)c(F)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
KDR P35968 6/20 0.37
FGFR3 P22607 1/20 0.37
TP53 P04637 2/20 0.36
CSF1R P07333 3/20 0.36
RET P07949 3/20 0.36
FLT1 P17948 3/20 0.36
MAP4K2 Q12851 3/20 0.36
STK3 Q13188 3/20 0.36
MAP4K5 Q9Y4K4 3/20 0.36
MAP4K4 O95819 2/20 0.36
LCK P06239 2/20 0.36
LRRK2 Q5S007 2/20 0.36
TAOK1 Q7L7X3 2/20 0.36
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477777 0.91 EGFR (0.39) MAPTKDM4EALDH1A1POLBRAB9A
SCHEMBL2477539 0.81 BRAF (0.47) KDRFGFR3FLT1LCKFYN
SCHEMBL2551894 0.77 KMT2A (0.39) MAPTKDM4EALDH1A1POLBRAB9A
SCHEMBL2480272 0.77 IGF1R (0.48) MAPTKDRFGFR3CSF1RRET
SCHEMBL2531622 0.73 CNR1 (0.37) MAPTKDM4EALDH1A1POLBRAB9A
SCHEMBL2477772 0.72 BRAF (0.47) MAPTKDRTP53GAAEGFR
SCHEMBL2477784 0.72 BRAF (0.41) KDRFYNEGFR
SCHEMBL2477831 0.71 TEK (0.48) KDRTEK
SCHEMBL2477787 0.70 BRAF (0.46) KDRCSF1RFLT1LCKIGF1R
SCHEMBL2477713 0.67 BRAF (0.44) KDRCSF1RFLT1LCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US claimed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP claimed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US claimed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP claimed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO claimed
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 MAPT 2667/4885KDM4E 975/4885ALDH1A1 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.